ArticleBiochemistry and biophysics reports2025
Caloric restriction mimetics chlorogenic acid and fisetin as potential autophagy inducers targeting ATG101.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is an important cytoprotective process impaired in neurodegenerative diseases such as Alzheimer's disease. The initiation process is mediated by the protein kinase Unc-51-like kinase 1 (ULK1) complex. ATG101, a cytosolic protein, plays a pivotal role in initiating autophagy as a component of the ULK complex in mammalian cells. It is important to understand the regulatory processes of individual autophagy components under different conditions for the development of therapeutic interventions. The caloric restriction mimetics (CRMs) such as chlorogenic acid (CGA) and fisetin mimic the healthy outcomes of caloric restriction without decreasing caloric consumption, constituting promising therapeutic candidates for neuroprotection. We explored the ATG101 interactions of CGA and fisetin in this work. Molecular docking and molecular dynamics (MD) simulations were used to investigate the interactions of these CRMs with ATG101, evaluating binding stability and dynamics. To confirm these interactions, we conducted quantitative real-time PCR (qRT-PCR) in differentiated SHSY5Y cells, analyzing the effect of CGA and fisetin on ATG101 gene expression. Our results indicated that fisetin forms a more stable complex with ATG101 compared to CGA. Yet, at the transcriptional level, both CRMs stimulate the mRNA level of ATG101. Therefore, these CRMs can be responsible for their potential as autophagy inducers. These findings offer significant insights into the molecular processes through which CRMs may improve neurodegenerative diseases by triggering autophagy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.